Role of the Epstein–Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Young LS, Rickinson AB: Epstein–Barr virus: 40 years on. Nat. Rev. Cancer4(10),757–768 (2004).▪▪ Timely review of the research highlights in the field since the original discovery of the virus.
  Medline CASGoogle Scholar
• 2  Chan AS, To KF, Lo KW et al.: High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res.60(19),5365–5370 (2000).
  Medline CASGoogle Scholar
• 3  Chan AS, To KF, Lo KW et al.: Frequent chromosome 9p losses in histologically normal nasopharyngeal epithelia from southern Chinese. Int. J. Cancer102(3),300–303 (2002).
  Medline CASGoogle Scholar
• 4  Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N: Clonal proliferations of cells infected with Epstein–Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med.333(11),693–698 (1995).▪▪ Critical findings demonstrating that Epstein–Barr virus infection is an early event that occurs prior to clonal expansion of a premalignant pool of cells.
  Medline CASGoogle Scholar
• 5  Wang D, Liebowitz D, Kieff E: An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell43(3 Part 2),831–840 (1985).
  Medline CASGoogle Scholar
• 6  Baichwal VR, Sugden B: Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein–Barr virus. Oncogene2(5),461–467 (1988).
  Medline CASGoogle Scholar
• 7  Kaye KM, Izumi KM, Kieff E: Epstein–Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA90(19),9150–9154 (1993).▪ A key study in establishing the role of latent membrane protein 1 (LMP1) in the transformation of B cells.
  Medline CASGoogle Scholar
• 8  Fahraeus R, Rymo L, Rhim JS, Klein G: Morphological transformation of human keratinocytes expressing the LMP gene of Epstein–Barr virus. Nature345(6274),447–449 (1990).▪ A key study in establishing the role of LMP1 in the transformation of epithelial cells.
  Medline CASGoogle Scholar
• 9  Dawson CW, Rickinson AB, Young LS: Epstein–Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature344(6268),777–780 (1990).▪ Another key report highlighting the profound effects of LMP1 expression in epithelial cells in culture.
  Medline CASGoogle Scholar
• 10  Stevenson D, Charalambous C, Wilson JB: Epstein–Barr virus latent membrane protein 1 (CAO) upregulates VEGF and TGF α concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9. Cancer Res.65(19),8826–8835 (2005).
  Medline CASGoogle Scholar
• 11  Brooks L, Yao QY, Rickinson AB, Young LS: Epstein–Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol.66(5),2689–2697 (1992).
  Medline CASGoogle Scholar
• 12  Young LS, Dawson CW, Clark D et al.: Epstein–Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol.69(Part 5),1051–1065 (1988).
  Medline CASGoogle Scholar
• 13  Khabir A, Karray H, Rodriguez S et al.: EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol. J.2,39 (2005).
  MedlineGoogle Scholar
• 14  Hu LF, Minarovits J, Cao SL et al.: Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein–Barr virus BNLF-1 5´-flanking region. J. Virol.65(3),1558–1567 (1991).
  Medline CASGoogle Scholar
• 15  Hu L, Troyanovsky B, Zhang X, Trivedi P, Ernberg I, Klein G: Differences in the immunogenicity of latent membrane protein 1 (LMP1) encoded by Epstein–Barr virus genomes derived from LMP1-positive and -negative nasopharyngeal carcinoma. Cancer Res.60(19),5589–5593 (2000).
  Medline CASGoogle Scholar
• 16  Trivedi P, Hu LF, Chen F et al.: Epstein–Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur. J. Cancer30A(1),84–88 (1994).
  Medline CASGoogle Scholar
• 17  Shao JY, Ernberg I, Biberfeld P, Heiden T, Zeng YX, Hu LF: Epstein–Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma. Anticancer Res.24(4),2309–2318 (2004).
  Medline CASGoogle Scholar
• 18  Niedobitek G, Meru N, Delecluse HJ: Epstein–Barr virus infection and human malignancies. Int. J. Exp. Pathol.82(3),149–170 (2001).
  Medline CASGoogle Scholar
• 19  Hammerschmidt W, Sugden B, Baichwal VR: The transforming domain alone of the latent membrane protein of Epstein–Barr virus is toxic to cells when expressed at high levels. J. Virol.63(6),2469–2475 (1989).▪▪ Critical findings highlighting the dose-dependent effects of LMP1 expression.
  Medline CASGoogle Scholar
• 20  Lu JJ, Chen JY, Hsu TY, Yu WC, Su IJ, Yang CS: Induction of apoptosis in epithelial cells by Epstein–Barr virus latent membrane protein 1. J. Gen. Virol.77(Part 8),1883–1892 (1996).
  Medline CASGoogle Scholar
• 21  Liu Y, Wang X, Lo AK, Wong YC, Cheung AL, Tsao SW: Latent membrane protein-1 of Epstein–Barr virus inhibits cell growth and induces sensitivity to cisplatin in nasopharyngeal carcinoma cells. J. Med. Virol.66(1),63–69 (2002).
  Medline CASGoogle Scholar
• 22  Du C, Wen B, Li D et al.: Downregulation of Epstein–Barr virus-encoded latent membrane protein-1 by arsenic trioxide in nasopharyngeal carcinoma cells. Tumori92(2),140–148 (2006).
  Medline CASGoogle Scholar
• 23  Gires O, Zimber-Strobl U, Gonnella R et al.: Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule. EMBO J.16(20),6131–6140 (1997).
  Medline CASGoogle Scholar
• 24  Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E: The Epstein–Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell80(3),389–399 (1995).
  Medline CASGoogle Scholar
• 25  Eliopoulos AG, Young LS: LMP1 structure and signal transduction. Semin. Cancer Biol.11(6),435–444 (2001).
  Medline CASGoogle Scholar
• 26  Uchida J, Yasui T, Takaoka-Shichijo Y et al.: Mimicry of CD40 signals by Epstein–Barr virus LMP1 in B lymphocyte responses. Science286(5438),300–303 (1999).
  Medline CASGoogle Scholar
• 27  Aviel S, Winberg G, Massucci M, Ciechanover A: Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue. J. Biol. Chem.275(31),23491–23499 (2000).
  Medline CASGoogle Scholar
• 28  Lo AK, To KF, Lo KW et al.: Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc. Natl. Acad. Sci. USA104(41),16164–16169 (2007).▪▪ Very interesting report highlighting a novel level of regulation of LMP1 expression.
  Medline CASGoogle Scholar
• 29  Kaykas A, Worringer K, Sugden B: LMP-1’s transmembrane domains encode multiple functions required for LMP-1’s efficient signaling. J. Virol.76(22),11551–11560 (2002).
  Medline CASGoogle Scholar
• 30  Puls A, Eliopoulos AG, Nobes CD, Bridges T, Young LS, Hall A: Activation of the small GTPase Cdc42 by the inflammatory cytokines TNF(α) and IL-1, and by the Epstein–Barr virus transforming protein LMP1. J. Cell Sci.112(Part 17),2983–2992 (1999).
  Medline CASGoogle Scholar
• 31  Eliopoulos AG, Stack M, Dawson CW et al.: Epstein–Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene14(24),2899–2916 (1997).
  Medline CASGoogle Scholar
• 32  Izumi KM, Kieff ED: The Epstein–Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc. Natl. Acad. Sci. USA94(23),12592–12597 (1997).
  Medline CASGoogle Scholar
• 33  Mainou BA, Everly DN Jr, Raab-Traub N: Epstein–Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene24(46),6917–6924 (2005).
  Medline CASGoogle Scholar
• 34  Sandberg M, Hammerschmidt W, Sugden B: Characterization of LMP-1’s association with TRAF1, TRAF2, and TRAF3. J. Virol.71(6),4649–4656 (1997).
  Medline CASGoogle Scholar
• 35  Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS: Epstein–Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol.73(2),1023–1035 (1999).
  Medline CASGoogle Scholar
• 36  Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS: Activation of the p38 mitogen-activated protein kinase pathway by Epstein–Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J. Biol. Chem.274(23),16085–16096 (1999).
  Medline CASGoogle Scholar
• 37  Chung PJ, Chang YS, Liang CL, Meng CL: Negative regulation of Epstein–Barr virus latent membrane protein 1-mediated functions by the bone morphogenetic protein receptor IA-binding protein, BRAM1. J. Biol. Chem.277(42),39850–39857 (2002).
  Medline CASGoogle Scholar
• 38  Li HP, Chang YS: Epstein–Barr virus latent membrane protein 1: structure and functions. J. Biomed. Sci.10(5),490–504 (2003).
  Medline CASGoogle Scholar
• 39  Dawson CW, Tramountanis G, Eliopoulos AG, Young LS: Epstein–Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J. Biol. Chem.278(6),3694–3704 (2003).
  Medline CASGoogle Scholar
• 40  Dawson CW, Laverick L, Morris MA, Tramoutanis G, Young LS: Epstein–Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK–MAPK pathway. J. Virol.82(7),3654–3664 (2008).
  Medline CASGoogle Scholar
• 41  Gires O, Kohlhuber F, Kilger E et al.: Latent membrane protein 1 of Epstein–Barr virus interacts with JAK3 and activates STAT proteins. EMBO J.18(11),3064–3073 (1999).
  Medline CASGoogle Scholar
• 42  Higuchi M, Kieff E, Izumi KM: The Epstein–Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines. J. Virol.76(1),455–459 (2002).
  Medline CASGoogle Scholar
• 43  Lo KW, To KF, Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell5(5),423–428 (2004).
  Medline CASGoogle Scholar
• 44  Tao Q, Chan AT: Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev. Mol. Med.9(12),1–24 (2007).
  MedlineGoogle Scholar
• 45  Soussi T, Ishioka C, Claustres M, Béroud C: Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer6(1),83–90 (2006).
  Medline CASGoogle Scholar
• 46  Crook T, Nicholls JM, Brooks L, O’Nions J, Allday MJ: High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene19(30),3439–3444 (2000).
  Medline CASGoogle Scholar
• 47  Chu WK, Lee KC, Chow SE, Chen JK: Dual regulation of the ΔNp63 transcriptional activity by ΔNp63 in human nasopharyngeal carcinoma cell. Biochem. Biophys. Res. Commun.342(4),1356–1360 (2006).
  Medline CASGoogle Scholar
• 48  Guo C, Pan ZG, Li DJ et al.: The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection. J. Transl. Med.4,23 (2006).
  MedlineGoogle Scholar
• 49  Lo KW, Mok CH, Huang DP et al.: p53 mutation in human nasopharyngeal carcinomas. Anticancer Res.12(6B),1957–1963 (1992).
  Medline CASGoogle Scholar
• 50  Spruck CH 3^rd, Tsai YC, Huang DP et al.: Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res.52(17),4787–4790 (1992).
  Medline CASGoogle Scholar
• 51  Chang KP, Hao SP, Lin SY et al.: A lack of association between p53 mutations and recurrent nasopharyngeal carcinomas refractory to radiotherapy. Laryngoscope112(11),2015–2019 (2002).
  Medline CASGoogle Scholar
• 52  Fries KL, Miller WE, Raab-Traub N: Epstein–Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J. Virol.70(12),8653–8659 (1996).
  Medline CASGoogle Scholar
• 53  Li L, Guo L, Tao Y et al.: Latent membrane protein 1 of Epstein–Barr virus regulates p53 phosphorylation through MAP kinases. Cancer Lett.255(2),219–231 (2007).
  Medline CASGoogle Scholar
• 54  Wu HC, Lu TY, Lee JJ et al.: MDM2 expression in EBV-infected nasopharyngeal carcinoma cells. Lab. Invest.84(12),1547–1556 (2004).
  Medline CASGoogle Scholar
• 55  Morris MA, Dawson CW, Wei W et al.: Epstein–Barr virus-encoded LMP1 induces a hyperproliferative and inflammatory gene expression programme in cultured keratinocytes. J. Gen. Virol.89(Part 11),2806–2820 (2008).
  Medline CASGoogle Scholar
• 56  Sheu LF, Chen A, Lee HS, Hsu HY, Yu DS: Cooperative interactions among p53, bcl-2 and Epstein–Barr virus latent membrane protein 1 in nasopharyngeal carcinoma cells. Pathol. Int.54(7),475–485 (2004).
  Medline CASGoogle Scholar
• 57  Man C, Rosa J, Lee LT et al.: Latent membrane protein 1 suppresses RASSF1A expression, disrupts microtubule structures and induces chromosomal aberrations in human epithelial cells. Oncogene26(21),3069–3080 (2007).
  Medline CASGoogle Scholar
• 58  Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet.25(3),315–319 (2000).
  Medline CASGoogle Scholar
• 59  Macdiarmid J, Stevenson D, Campbell DH, Wilson JB: The latent membrane protein 1 of Epstein–Barr virus and loss of the INK4a locus: paradoxes resolve to cooperation in carcinogenesis in vivo. Carcinogenesis24(7),1209–1218 (2003).
  Medline CASGoogle Scholar
• 60  Zheng H, Li LL, Hu DS, Deng XY, Cao Y: Role of Epstein–Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell. Mol. Immunol.4(3),185–196 (2007).▪▪ Excellent review of the functions of LMP1 in modulating aspects of the cell cycle.
  Medline CASGoogle Scholar
• 61  Everly DN Jr, Mainou BA, Raab-Traub N: The ID proteins contribute to the growth of rodent fibroblasts during LMP1-mediated transformation. Virology376(2),258–269 (2008).
  Medline CASGoogle Scholar
• 62  Cheung ST, Huang DP, Hui AB et al.: Nasopharyngeal carcinoma cell line (C666–1) consistently harbouring Epstein–Barr virus. Int. J. Cancer83(1),121–126 (1999).
  Medline CASGoogle Scholar
• 63  Mei YP, Zhou JM, Wang Y et al.: Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle6(11),1379–1385 (2007).
  Medline CASGoogle Scholar
• 64  Li XP, Li G, Peng Y, Kung HF, Lin MC: Suppression of Epstein–Barr virus-encoded latent membrane protein-1 by RNA interference inhibits the metastatic potential of nasopharyngeal carcinoma cells. Biochem. Biophys. Res. Commun.315(1),212–218 (2004).
  Medline CASGoogle Scholar
• 65  Jin X, Song X, Li L et al.: Blockade of AP-1 activity by dominant-negative TAM67 can abrogate the oncogenic phenotype in latent membrane protein 1-positive human nasopharyngeal carcinoma. Mol. Carcinog.46(11),901–911 (2007).
  Medline CASGoogle Scholar
• 66  Ai MD, Li LL, Zhao XR, Wu Y, Gong JP, Cao Y: Regulation of survivin and CDK4 by Epstein–Barr virus encoded latent membrane protein 1 in nasopharyngeal carcinoma cell lines. Cell Res.15(10),777–784 (2005).
  Medline CASGoogle Scholar
• 67  Seo SY, Kim EO, Jang KL: Epstein–Barr virus latent membrane protein 1 suppresses the growth-inhibitory effect of retinoic acid by inhibiting retinoic acid receptor-β2 expression via DNA methylation. Cancer Lett.270(1),66–76 (2008).
  Medline CASGoogle Scholar
• 68  Tao Y, Song X, Deng X et al.: Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein–Barr-encoded oncoprotein latent membrane protein 1. Exp. Cell Res.303(2),240–251 (2005).
  Medline CASGoogle Scholar
• 69  Liu B, Chen XY: [Effect of EB virus latent membrane protein 1 on mitosis control of nasopharyngeal carcinoma cell line CNE1]. Ai Zheng23(5),512–516 (2004).
  Medline CASGoogle Scholar
• 70  Li G, Li XP, Peng Y, Liu X, Li XH: Effect of inhibition of EBV-encoded latent membrane protein-1 by small interfering RNA on EBV-positive nasopharyngeal carcinoma cell growth. Di Yi Jun Yi Da Xue Xue Bao24(3),241–246 (2004).
  Medline CASGoogle Scholar
• 71  Lin X, Liu S, Luo et al.: EBV-encoded LMP1 regulates Op18/stathmin signaling pathway by cdc2 mediation in nasopharyngeal carcinoma cells. Int. J. Cancer124(5),1020–1027 (2009).
  Medline CASGoogle Scholar
• 72  Ding L, Li LL, Yang et al.: Epstein–Barr virus encoded latent membrane protein 1 modulates nuclear translocation of telomerase reverse transcriptase protein by activating nuclear factor-κB p65 in human nasopharyngeal carcinoma cells. Int. J. Biochem. Cell Biol.37(9),1881–1889 (2005).
  Medline CASGoogle Scholar
• 73  Siegler G, Meyer B, Dawson C et al.: Expression of tumor necrosis factor receptor-associated factor 1 in nasopharyngeal carcinoma: possible upregulation by Epstein–Barr virus latent membrane protein 1. Int. J. Cancer112(2),265–272 (2004).
  Medline CASGoogle Scholar
• 74  Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML: Interleukin-6 inhibits transforming growth factor-β-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J. Biol. Chem.274(33),23013–23019 (1999).
  Medline CASGoogle Scholar
• 75  Wheelock MJ, Johnson KR: Cadherins as modulators of cellular phenotype. Annu. Rev. Cell Dev. Biol.19,207–235 (2003).
  Medline CASGoogle Scholar
• 76  Fahraeus R, Chen W, Trivedi P, Klein G, Obrink B: Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells. Int. J. Cancer52(5),834–838 (1992).
  Medline CASGoogle Scholar
• 77  Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS: The Epstein–Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc. Natl. Acad. Sci. USA99(15),10084–10089 (2002).
  Medline CASGoogle Scholar
• 78  Horikawa T, Yang J, Kondo S et al.: Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res.67(5),1970–1978 (2007).
  Medline CASGoogle Scholar
• 79  Tsai CL, Li HP, Lu YJ et al.: Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res.66(24),11668–11676 (2006).
  Medline CASGoogle Scholar
• 80  Krishna SM, Kattoor J, Balaram P: Down regulation of adhesion protein E-cadherin in Epstein–Barr virus infected nasopharyngeal carcinomas. Cancer Biomark.1(6),271–277 (2005).
  Medline CASGoogle Scholar
• 81  Zhang ZW, He ZM, Zhou M, Ding W, Yu YH, Chen ZC: [Mechanism of migration in CNE2 cells promoted by EBV-LMP1]. Zhong Nan Da Xue Xue Bao Yi Xue Ban31(4),470–474 (2006).
  Medline CASGoogle Scholar
• 82  Shair KH, Schnegg CI, Raab-Traub N: EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res.68(17),6997–7005 (2008).
  Medline CASGoogle Scholar
• 83  Gendler SJ: MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia6(3),339–353 (2001).
  Medline CASGoogle Scholar
• 84  Kim YS, Gum J Jr, Brockhausen I: Mucin glycoproteins in neoplasia. Glycoconj. J.13(5),693–707 (1996).
  Medline CASGoogle Scholar
• 85  Lee MJ, Lee HS, Kim WH, Choi Y, Yang M: Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod. Pathol.16(5),403–410 (2003).
  MedlineGoogle Scholar
• 86  Ringel J, Lohr M: The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol. Cancer2,9 (2003).
  MedlineGoogle Scholar
• 87  Taylor-Papadimitriou J, Burchell JM, Plunkett T et al.: MUC1 and the immunobiology of cancer. J. Mammary Gland Biol. Neoplasia7(2),209–221 (2002).
  MedlineGoogle Scholar
• 88  Baldus SE, Engelmann K, Hanisch FG: MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit. Rev. Clin. Lab. Sci.41(2),189–231 (2004).
  Medline CASGoogle Scholar
• 89  Kondo S, Yoshizaki T, Wakisaka N et al.: MUC1 induced by Epstein–Barr virus latent membrane protein 1 causes dissociation of the cell-matrix interaction and cellular invasiveness via STAT signaling. J. Virol.81(4),1554–1562 (2007).
  Medline CASGoogle Scholar
• 90  Lo AK, Liu Y, Wang XH et al.: Alterations of biologic properties and gene expression in nasopharyngeal epithelial cells by the Epstein–Barr virus-encoded latent membrane protein 1. Lab. Invest.83(5),697–709 (2003).
  Medline CASGoogle Scholar
• 91  Liu LT, Peng JP, Chang HC, Hung WC: RECK is a target of Epstein–Barr virus latent membrane protein 1. Oncogene22(51),8263–8270 (2003).
  Medline CASGoogle Scholar
• 92  Kim KR, Yoshizaki T, Miyamori H et al.: Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein–Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene19(14),1764–1771 (2000).
  Medline CASGoogle Scholar
• 93  Zeng L, Liu YP, Wang H et al.: [EB virus encoded latent membrane protein 1 mediated expression of transcription factor Ets-1 in nasopharyngeal carcinoma cells]. Zhonghua Zhong Liu Za Zhi26(8),454–457 (2004).
  Medline CASGoogle Scholar
• 94  Kwok Fung Lo A, Liu Y, Wang X et al.: Identification of downstream target genes of latent membrane protein 1 in nasopharyngeal carcinoma cells by suppression subtractive hybridization. Biochim. Biophys. Acta1520(2),131–140 (2001).
  Medline CASGoogle Scholar
• 95  Yang J, Mani SA, Donaher JL et al.: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell117(7),927–939 (2004).
  Medline CASGoogle Scholar
• 96  Shen ZH, Chen XY, Chen J: [Impact of up-regulating Ezrin expression by Epstein–Barr virus latent membrane protein 1 on metastasis ability of nasopharyngeal carcinoma cells]. Ai Zheng27(2),165–169 (2008).
  Medline CASGoogle Scholar
• 97  Liu QY, Han AJ, You SY et al.: [Correlation of Epstein–Barr virus-encoded latent membrane protein 1 (LMP1) to fascin and phosphorylated Stat3 in nasopharyngeal carcinoma]. Ai Zheng27(10),1070–1076 (2008).
  Medline CASGoogle Scholar
• 98  Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M, Yoshizaki T: Induction of c-Met proto-oncogene by Epstein–Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am. J. Pathol.159(1),27–33 (2001).
  Medline CASGoogle Scholar
• 99  Lukashev ME, Werb Z: ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol.8(11),437–441 (1998).
  Medline CASGoogle Scholar
• 100  Yoshizaki T: Promotion of metastasis in nasopharyngeal carcinoma by Epstein–Barr virus latent membrane protein-1. Histol. Histopathol.17(3),845–850 (2002).
  Medline CASGoogle Scholar
• 101  Gou XM, Chen Y, Chen XY, Arrand JR: [Effects of Epstein–Barr virus latent membrane protein 1(EBV-LMP1) on related factors of metastasis of nasopharyngeal carcinoma cell line CNE1]. Ai Zheng22(5),481–485 (2003).
  Medline CASGoogle Scholar
• 102  Yoshizaki T, Sato H, Furukawa M, Pagano JS: The expression of matrix metalloproteinase 9 is enhanced by Epstein–Barr virus latent membrane protein 1. Proc. Natl. Acad. Sci. USA95(7),3621–3626 (1998).
  Medline CASGoogle Scholar
• 103  Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M: Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer89(4),715–723 (2000).
  Medline CASGoogle Scholar
• 104  Kondo S, Wakisaka N, Schell MJ et al.: Epstein–Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int. J. Cancer115(3),368–376 (2005).
  Medline CASGoogle Scholar
• 105  Zeng L, Liu YP, Tao YG, Ai MD, Zhao XR, Cao Y: [Cross-talk between c-Jun/Ets1 involved in EB virus-encoded latent membrane protein 1 regulates expression of matrix metalloproteinase-9 in nasopharyngeal carcinoma]. Zhonghua Zhong Liu Za Zhi27(4),204–208 (2005).
  Medline CASGoogle Scholar
• 106  Bergers G, Brekken R, McMahon G et al.: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol.2(10),737–744 (2000).
  Medline CASGoogle Scholar
• 107  Murono S, Yoshizaki T, Sato H, Takeshita H, Furukawa M, Pagano JS: Aspirin inhibits tumor cell invasiveness induced by Epstein–Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res.60(9),2555–2561 (2000).
  Medline CASGoogle Scholar
• 108  Lee DC, Chua DT, Wei WI, Sham JS, Lau AS: Induction of matrix metalloproteinases by Epstein–Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma. Biomed. Pharmacother.61(9),520–526 (2007).
  Medline CASGoogle Scholar
• 109  Chang SH, Chang HC, Hung WC: Transcriptional repression of tissue inhibitor of metalloproteinase-3 by Epstein–Barr virus latent membrane protein 1 enhances invasiveness of nasopharyngeal carcinoma cells. Oral Oncol.44(9),891–897 (2008).
  Medline CASGoogle Scholar
• 110  Kondo S, Seo SY, Yoshizaki T et al.: EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1α through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res.66(20),9870–9877 (2006).
  Medline CASGoogle Scholar
• 111  Murono S, Inoue H, Tanabe T et al.: Induction of cyclooxygenase-2 by Epstein–Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc. Natl. Acad. Sci. USA98(12),6905–6910 (2001).
  Medline CASGoogle Scholar
• 112  Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS: Epstein–Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 α. Mol. Cell. Biol.24(12),5223–5234 (2004).
  Medline CASGoogle Scholar
• 113  Yoshizaki T, Horikawa T, Qing-Chun R et al.: Induction of interleukin-8 by Epstein–Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin. Cancer Res.7(7),1946–1951 (2001).
  Medline CASGoogle Scholar
• 114  Ren Q, Sato H, Murono S, Furukawa M, Yoshizaki T: Epstein–Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-κ B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line. Laryngoscope114(5),855–859 (2004).
  Medline CASGoogle Scholar
• 115  Tsuji A, Wakisaka N, Kondo S, Murono S, Furukawa M, Yoshizaki T: Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma. Clin. Cancer Res.14(17),5368–5375 (2008).
  Medline CASGoogle Scholar
• 116  Edwards RH, Sitki-Green D, Moore DT, Raab-Traub N: Potential selection of LMP1 variants in nasopharyngeal carcinoma. J. Virol.78(2),868–881 (2004).
  Medline CASGoogle Scholar
• 117  Burrows JM et al.: Selection pressure-driven evolution of the Epstein–Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia. J. Virol.78(13),7131–7137 (2004).
  Medline CASGoogle Scholar
• 118  Chen ML, Tsai CN, Liang CL et al.: Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein–Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene7(11),2131–2140 (1992).
  Medline CASGoogle Scholar
• 119  Hu LF, Zabarovsky ER, Chen F et al.: Isolation and sequencing of the Epstein–Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J. Gen. Virol.72(Part 10),2399–2409 (1991).
  Medline CASGoogle Scholar
• 120  Li SN, Chang YS, Liu ST: Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein–Barr virus. Oncogene12(10),2129–2135 (1996).
  Medline CASGoogle Scholar
• 121  Blake SM, Eliopoulos AG, Dawson CW, Young LS: The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology282(2),278–287 (2001).
  Medline CASGoogle Scholar
• 122  Dawson CW, Eliopoulos AG, Blake SM, Barker R, Young LS: Identification of functional differences between prototype Epstein–Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells. Virology272(1),204–217 (2000).
  Medline CASGoogle Scholar
• 123  Fielding CA, Sandvej K, Mehl A, Brennan P, Jones M, Rowe M: Epstein–Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J. Virol.75(19),9129–9141 (2001).
  Medline CASGoogle Scholar
• 124  Nitta T, Chiba A, Yamamoto N, Yamaoka S: Lack of cytotoxic property in a variant of Epstein–Barr virus latent membrane protein-1 isolated from nasopharyngeal carcinoma. Cell Signal.16(9),1071–1081 (2004).
  Medline CASGoogle Scholar
• 125  Huang H, Huang PC: [Effects of two LMP1 variants on resistance of CNE1 cell strain to TGF-β1]. Ai Zheng22(12),1254–1259 (2003).
  Medline CASGoogle Scholar
• 126  Hadhri-Guiga B, Chiba A, Yamamoto N, Yamaoka S: Various 30 and 69 bp deletion variants of the Epstein–Barr virus LMP1 may arise by homologous recombination in nasopharyngeal carcinoma of Tunisian patients. Virus Res.115(1),24–30 (2006).
  Medline CASGoogle Scholar
• 127  Khanim F, Yao QY, Niedobitek G, Sihota S, Rickinson AB, Young LS: Analysis of Epstein–Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood88(9),3491–3501 (1996).
  Medline CASGoogle Scholar
• 128  Chang KP, Hao SP, Lin SY et al.: The 30-bp deletion of Epstein–Barr virus latent membrane protein-1 gene has no effect in nasopharyngeal carcinoma. Laryngoscope116(4),541–546 (2006).
  Medline CASGoogle Scholar